N⁶,N⁶-bis(tert-butoxycarbonyl)-5'-O-sulfamoyl-2',3'-O-isopropylideneadenosine | 1094677-80-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N⁶,N⁶-bis(tert-butoxycarbonyl)-5'-O-sulfamoyl-2',3'-O-isopropylideneadenosine
• 英文别名: N(6),N(6)-bis(tert-butoxycarbonyl)-2',3'-O-isopropylidene-5'-O-sulfamoyladenosine；tert-butyl N-[9-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-(sulfamoyloxymethyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]purin-6-yl]-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
• CAS: 1094677-80-1
• 化学式: C₂₃H₃₄N₆O₁₀S
• 分子量: 586.623
• InChiKey: UVWJEUBAYUFDGQ-SCFUHWHPSA-N

物化性质

• 沸点：
  702.0±70.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  205
• 氢给体数：
  1
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  N⁶,N⁶-bis(tert-butoxycarbonyl)-5'-O-sulfamoyl-2',3'-O-isopropylideneadenosine 在 吡啶 、 palladium on activated charcoal 、 氢气 、 caesium carbonate 、 三氟乙酸 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.25h， 生成 2′,3′-O-diacetyl-5′-O-[N-(2-hydroxybenzoyl)sulfamoyl]adenosine triethylammonium salt
  参考文献：
  名称：

  结核分枝杆菌铁载体生物合成抑制剂的合成及药代动力学评价

  摘要：

  MbtA催化分枝杆菌素的第一个重要的生物合成步骤，这是与结核分枝杆菌中铁摄入有关的重要毒力因子。MbtA是抗结核药物开发的经过验证的治疗靶标。5'- O- [ N-（水杨基）氨磺酰基]腺苷（1）是MbtA的双底物抑制剂，具有极强的生化和抗结核活性。然而，1的药物处置特性欠佳，导致半衰期短（t 1/2），低暴露（AUC）和低生物利用度（F）。采取了四种策略来解决这些问题，包括前药的合成，增加酰基磺酰基部分的p K a，调节亲脂性以及将氟引入1的策略。对所有化合物进行了完整的药代动力学（PK）分析。最成功的修饰涉及核苷的氟化，这可显着改善t 1/2和AUC。增加酰基-磺酰基接头的p K a会产生增量的增强，而亲脂性和前药方法的调节则导致PK参数大大降低。

  DOI：

  10.1021/acs.jmedchem.5b00391
• 作为产物：
  描述：

  N,N-二[叔丁氧羰基]-2',3'-O-(异丙亚基)腺苷 、 氨基磺酰氯 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N⁶,N⁶-bis(tert-butoxycarbonyl)-5'-O-sulfamoyl-2',3'-O-isopropylideneadenosine
  参考文献：
  名称：

  A critical electrostatic interaction mediates inhibitor recognition by human asparagine synthetase

  摘要：

  The first sulfoximine-based inhibitor of human asparagine synthetase (ASNS) with nanomolar potency has been shown to suppress proliferation of asparaginase-resistant MOLT-4 cells in the presence of L-asparaginase. This validates literature hypotheses concerning the viability of human ASNS as a target for new drugs against acute lymphoblastic leukemia and ovarian cancer. Developing structure-function relationships for this class of human ASNS inhibitors has proven diffcult, however, primarily because of the absence of rapid synthetic procedures for constructing highly functionalized sulfoximines. We now report conditions for the efficient preparation of these compounds by coupling sulfoxides and sulfamides in the presence of a rhodium catalyst. Access to this methodology has permitted the construction of two new adenylated sulfoximines, which were expected to exhibit similar binding affinity and better bioavailability than the original human ASNS inhibitor. Steady-state kinetic characterization of these compounds, however, has revealed the importance of a localized negative charge on the inhibitor that mimics that of the phosphate group in a key acyl-adenylate reaction intermediate. These experiments place an important constraint on the design of sulfoximine libraries for screening experiments to obtain ASNS inhibitors with increased potency and bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.07.071

文献信息

• Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis
  作者：Marzena Baran、Kimberly D. Grimes、Paul A. Sibbald、Peng Fu、Helena I.M. Boshoff、Daniel J. Wilson、Courtney C. Aldrich

  DOI：10.1016/j.ejmech.2020.112408

  日期：2020.9

  biochemical roles of many FACLs remain poorly characterized while the functionally non-redundant FAALs are much better understood. Here we describe the systematic investigation of 5′-O-[N-(alkanoyl)sulfamoyl]adenosine (alkanoyl adenosine monosulfamate, alkanoyl-AMS) analogs as potential multitarget FadD inhibitors for their antitubercular activity and biochemical selectivity towards representative FAAL and

  结核分枝杆菌( Mtb ) 的脂质代谢依赖 34 种脂肪酸腺苷酸化酶 (FAdDs)，可分为两类：参与脂质和胆固醇分解代谢的脂肪酰基辅酶 A 连接酶 (FACL) 和长链脂肪酰基-AMP 连接酶 (FAAL) ) 参与Mtb 中发现的许多必需和赋予毒力的脂质的生物合成。许多 FACL 的精确生化作用仍不清楚，而功能非冗余的 FAAL 则更好理解。这里，我们描述的5'-系统调查ö - [ ñ - （链烷酰基）氨磺酰基]腺苷（烷酰基一denosine米ONO小号ulFAa href=https://www.molaid.com/MS_77914 target="_blank">AMate, alkanoyl-AMS) 类似物作为潜在的多靶点 FAdD 抑制剂，因为它们具有抗结核活性和对代表性 FAAL 和 FACL 酶的生化选择性。我们鉴定了几种有效的化合物，包括 12-叠氮十二烷酰基-AMS 28、11-苯氧基十一烷酰基-AMS 32和壬氧基乙酰基-AMS 36，其对结核分枝杆菌的最小抑制浓度 (MIC)范围为
• Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis
  作者：Xuequan Lu、Huaning Zhang、Peter J. Tonge、Derek S. Tan

  DOI：10.1016/j.bmcl.2008.07.130

  日期：2008.11

  Menaquinone (vitamin K(2)) is an essential component of the electron transfer chain in many pathogens, including Mycobacterium tuberculosis and Staphylococcus aureus, and menaquinone biosynthesis is a potential target for antibiotic drug discovery. We report herein a series of mechanism-based inhibitors of MenE, an acyl-CoA synthetase that catalyzes adenylation and thioesterification of o-succinylbenzoic

  甲萘醌（维生素 K(2)）是许多病原体（包括结核分枝杆菌和金黄色葡萄球菌）中电子传递链的重要组成部分，甲萘醌生物合成是抗生素药物发现的潜在目标。我们在此报告了一系列基于机制的 MenE 抑制剂，MenE 是一种酰基辅酶 A 合成酶，可在甲基萘醌生物合成过程中催化邻琥珀酰苯甲酸 (OSB) 的腺苷酸化和硫酯化。最有效的化合物以 5.7microM 的 IC(50) 值抑制 MenE。
• [EN] INHIBITORS OF MENAQUINONE BIOSYNTHESIS<br/>[FR] INHIBITEURS DE LA BIOSYNTHÈSE DE LA MÉNAQUINONE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2017059411A9

  公开（公告）日：2017-08-31